Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Whitehawk Therapeutics, Inc.ARPO · Entity 6074 | Vice President of Finance | March 16, 2020 | March 18, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Whitehawk Therapeutics, Inc.
Report date March 16, 2020 · Filed March 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.52 · Expires 2030-03-16 | Direct | 93,000 |
Reported balance
After 2020-03-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-03-16 · Grant · Acquired 93,000 · Balance 93,000 F1: Options exercisable as to 1/4th on March 16, 2021 and an additional 1/48th monthly thereafter until March 16, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Options exercisable as to 1/4th on March 16, 2021 and an additional 1/48th monthly thereafter until March 16, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 16, 2020 Filed Mar 18, 2020 22:09 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 93,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0000899243-20-008921 · doc4.xml · derivative · entry 1 Marek Regina · CIK 0001792048 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,000 Underlying: Common Stock · 93,000 shares Expires 2030-03-16 F1 · derivative.exercise_date: Options exercisable as to 1/4th on March 16, 2021 and an additional 1/48th monthly thereafter until March 16, 2024. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 21:15 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 44,300 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0000899243-19-026769 · doc4.xml · derivative · entry 1 Marek Regina · CIK 0001792048 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,300 Underlying: Common Stock · 44,300 shares Expires 2029-11-04 F1 · derivative.exercise_date: Options exercisable as to 1/4th on February 15, 2020 and an additional 1/48th monthly thereafter until February 15, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.